PAX5 and chronic kidney disease: We used combinations of biomarkers to determine if discrimination could be significantly enhanced in comparison to the individual biomarkers; we found that a CKD‐MBD panel (BSAP, CTx) had highest discrimination in trabecular bone and that a miRNA panel had highest discrimination in endocortical and intracortical bone.